"You don't want to be waiting. Just get on with it": Experiences of hepatitis C point of care testing and same-day treatment

Authors:

<u>Douglass CH</u>¹, Vella-Horne D¹, Elsum I¹, Allardice K¹, Guzman R¹, Heath K¹, Higgs P¹, Hellard M¹, Wade A¹, Bryant M¹, Walsh L¹, Lancaster K^{2,3}, Rhodes T^{2,4}, Moullin J⁵. Stoove M¹, Doyle J¹, Pedrana A¹

¹Burnet Institute, Melbourne, Australia, ²Centre for Social Research in Health, University of New South Wales, Sydney, Australia, ³Goldsmiths University of London, United Kingdom, ⁴London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁵School of Population Health, Curtin University, Perth, Australia

Background: Accessing hepatitis C virus (HCV) treatment involves multiple steps. Advances in point of care (POC) testing means it is possible to diagnose HCV and access treatment in a single visit. However, few studies have investigated this model. We explored people's experiences with POC testing and same-day treatment.

Methods: We conducted a qualitative sub-study within QuickStart, a randomised trial in Australian primary healthcare clinics. QuickStart compared three arms: Arm A (POC antibody testing and standard care), Arm B (POC antibody testing, POC RNA testing and standard care) and Arm C (offering same-day treatment following a positive POC antibody result). We interviewed 17 participants about their experiences with the interventions. Analysis was informed by the Capabilities, Opportunities and Motivations model for Behaviour change.

Results: Capabilities: Compared to venipuncture, most participants found POC testing quick and easy. Some Arm B participants felt that waiting >60 minutes for a POC RNA result was too long given they had busy lives and family responsibilities. Opportunities: Across intervention arms, participants valued support from a friendly and non-judgmental study nurse. For Arm C participants, provision of free medication on the same day made commencing HCV treatment an easier choice. However, some Arm C participants preferred to wait for confirmation of their HCV status from venipuncture to avoid starting medication they may not need and experiencing potential side effects like tiredness. Motivation: Across study arms, participants were motivated to take part in QuickStart to improve their health and ensure they were around for their families in the future. Financial incentives (\$40 for a POC test and \$80 for a 12-week follow-up visit after treatment) were perceived as an added bonus.

Conclusion: POC testing and same-day treatment addressed some barriers to accessing HCV care. Other important factors included non-judgmental nurses, an opportunity to improve health and financial incentives.

Disclosure of Interest Statement: QuickStart was funded by Gilead Sciences and an NHMRC clinical trials grant. MH, JD, MS, AP have received investigator-initiated research funding from Gilead Sciences and AbbVie. JD, MS and AP have received consultant fees from Gilead Sciences for activities unrelated to this work.